- Home
- IGC vs CRIS Comparison
IGC vs CRIS Comparison
Compare IGC & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- CRIS
- Stock Information
- Founded
- IGC 2005
- CRIS 2000
- Country
- IGC United States
- CRIS United States
- Employees
- IGC N/A
- CRIS N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGC Health Care
- CRIS Health Care
- Exchange
- IGC Nasdaq
- CRIS Nasdaq
- Market Cap
- IGC 20.2M
- CRIS 21.3M
- IPO Year
- IGC N/A
- CRIS 2000
- Fundamental
- Price
- IGC $0.31
- CRIS $2.32
- Analyst Decision
- IGC Strong Buy
- CRIS Strong Buy
- Analyst Count
- IGC 2
- CRIS 2
- Target Price
- IGC $3.88
- CRIS $16.50
- AVG Volume (30 Days)
- IGC 246.3K
- CRIS 71.8K
- Earning Date
- IGC 06-27-2025
- CRIS 07-31-2025
- Dividend Yield
- IGC N/A
- CRIS N/A
- EPS Growth
- IGC N/A
- CRIS N/A
- EPS
- IGC N/A
- CRIS N/A
- Revenue
- IGC $1,271,000.00
- CRIS $11,202,000.00
- Revenue This Year
- IGC $15.26
- CRIS N/A
- Revenue Next Year
- IGC $3.41
- CRIS $10.67
- P/E Ratio
- IGC N/A
- CRIS N/A
- Revenue Growth
- IGC N/A
- CRIS 14.17
- 52 Week Low
- IGC $0.25
- CRIS $1.02
- 52 Week High
- IGC $0.50
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- IGC 52.79
- CRIS 52.52
- Support Level
- IGC $0.30
- CRIS $2.11
- Resistance Level
- IGC $0.32
- CRIS $2.26
- Average True Range (ATR)
- IGC 0.01
- CRIS 0.21
- MACD
- IGC 0.00
- CRIS -0.04
- Stochastic Oscillator
- IGC 33.33
- CRIS 21.36
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.